Evidence map›Paper›PMID 41739190›Full record

ArticleCancer immunology, immunotherapy : CII2026

Heterologous prime-boost immunization of AAV-based neoantigen cancer vaccine induces anti-tumor immunity to inhibit tumor growth and relapse.

Chi-Hsien Huang, Jhen-Yu Chen, Hsin-Yu Chang, Wei-Ze Hong, Yi-Wen Jiang, Chien-Yueh Lee, Chia-Hsin Wu, Yu-Sen Lin, Yuan-Yao Tsai, Wei-Ling Kao and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chi-Hsien HuangGraduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
Jhen-Yu ChenDepartment of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan.
Hsin-Yu ChangProton Therapy and Science Center, China Medical University Hospital, China Medical University, Taichung, Taiwan.
Wei-Ze HongDepartment of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan.
Yi-Wen JiangDepartment of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan.
Chien-Yueh LeeInnovation Frontier Institute of Research for Science and Technology, National Taipei University of Technology, Taipei, Taiwan.
Chia-Hsin WuBioinformatics and Biostatistics Core, Centers of Genomic and Precision Medicine, National Taiwan University, Taipei, Taiwan.
Yu-Sen LinDepartment of Chest Surgery, China Medical University Hospital, Taichung, Taiwan.
Yuan-Yao TsaiGraduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
Wei-Ling KaoDepartment of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan.
K S Clifford ChaoGraduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.ORCID http://orcid.org/0000-0002-7162-2566
Kevin Chih-Yang HuangDepartment of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan. chihyang0425@mail.cmu.edu.tw.ORCID http://orcid.org/0000-0002-0266-3233

Funding

China Medical University Hospital DMR-113-088Ministry of Science and Technology, Taiwan MOST110-2314-B-039-032Ministry of Science and Technology, Taiwan MOST110-2628-B-039-005
6 · The paper itself

Abstract

Therapeutic cancer vaccines, which induce anti-tumor immunity by targeting specific antigens, constitute a promising approach to cancer therapy. Our previous work developed a novel engineered adenovirus-associated virus 2 (AAV2)-based tumor-specific (neoantigen) cancer vaccine to boost antitumor immunity in combination with radiotherapy, resulting in tumor regression and less distant metastasis. However, the therapeutic efficacy of constitutive vector-based vaccination may be limited by poor immunogenicity, pre-existing vector-specific immunity, and vaccine-induced vector-specific immunity. Here, we examined the combinational therapeutic efficacy of AAV-based cancer vaccine, local radiotherapy, and immune checkpoint blockade (ICB) in different poorly immunogenic cancer animal models. We found that administration with AAV-based neoantigen vaccine significantly increased the response to radiotherapy and ICB, and decreased the risk of distant metastasis. Furthermore, we evaluated a heterologous prime-boost immunization strategy using two optimized AAV serotype vaccines to amplify tumor-specific immunity to neoantigens. These optimized AAV2/AAV6 neoantigen vaccine displayed strong immunogenicity with potent induction of CD8

Indexed as

Antigens, NeoplasmCancer VaccinesDependovirusNeoplasm Recurrence, LocalAnimalsCD8-Positive T-LymphocytesCell Line, TumorFemaleGenetic VectorsHumansImmunization, SecondaryMiceMice, Inbred C57BLAntigens, NeoplasmCancer VaccinesAdenovirus-associated virusCancer vaccineImmunotherapyRadiotherapyTumor microenvironment

Identifiers

PMID41739190
PMCPMC12936311

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.